
Sundar Narayanan to Serve as NewHydrogen Director of Process Engineering
Santa Clarita, California, May 20, 2025 (GLOBE NEWSWIRE) — NewHydrogen, Inc. (OTCQB:NEWH), the developer of ThermoLoop™, a breakthrough technology that uses water and heat rather than renewable electricity to produce the world's cheapest green hydrogen, today announced the appointment of Sundar Narayanan as Director of Process Engineering.
With over 35 years of experience in process development, scale-up, and commercialization, Mr. Narayanan brings deep expertise in chemical process design and innovation. His career spans leadership roles at major institutions including ExxonMobil Research & Engineering and Aspen Technology, where he spearheaded energy efficiency improvements, developed and implemented automated process monitoring systems, and provided technical direction for integrating advanced technologies such as molten carbonate fuel cells.
'Few engineers possess Sundar's level of practical and technical depth in process development and systems integration,' said Steve Hill, CEO of NewHydrogen. 'His experience evaluating, adapting, and commercializing novel technologies aligns perfectly with our mission to deliver the world's cheapest green hydrogen.'
'I'm excited to join the talented team at NewHydrogen and help advance a truly game-changing technology,' said Narayanan. 'Scaling up ThermoLoop™ is a unique opportunity to apply decades of process engineering knowledge to accelerate the transition to clean, cost-effective hydrogen.'
Mr. Narayanan has been a key contributor to several high-impact publications and patents in energy efficiency and emissions reduction, and he continues to consult with cleantech innovators like C-Zero. He holds a B.Tech. in Chemical Engineering from the University of Madras and an M.S. in Chemical Engineering from the University of Akron.
At NewHydrogen, Mr. Narayanan will play a central role in refining and scaling the company's ThermoLoop™ technology as it moves toward pilot deployment.
To learn more about NewHydrogen's work with leading scientists at UC Santa Barbara to develop the world's cheapest green hydrogen, please visit NewHydrogen.com.
About NewHydrogen, Inc.
NewHydrogen is developing ThermoLoop™ – a breakthrough technology that uses water and heat rather than electricity to produce the world's lowest cost green hydrogen. Hydrogen is the cleanest and most abundant element in the universe, and we can't live without it. Hydrogen is the key ingredient in making fertilizers needed to grow food for the world. It is also used for transportation, refining oil and making steel, glass, pharmaceuticals and more. Nearly all the hydrogen today is made from hydrocarbons like coal, oil, and natural gas, which are dirty and limited resources. Water, on the other hand, is an infinite and renewable worldwide resource.
Currently, the most common method of making green hydrogen is to split water into oxygen and hydrogen with an electrolyzer using green electricity produced from solar or wind. However, green electricity is and always will be very expensive. It currently accounts for 73% of the cost of green hydrogen. By using heat directly, we can skip the expensive process of making electricity, and fundamentally lower the cost of green hydrogen. Inexpensive heat can be obtained from concentrated solar, geothermal, nuclear reactors and industrial waste heat for use in our novel low-cost thermochemical water splitting process. Working with a world class research team at UC Santa Barbara, our goal is to help usher in the green hydrogen economy that Goldman Sachs estimated to have a future market value of $12 trillion.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'may,' 'intend,' 'expect' and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, the impact on the national and local economies resulting from terrorist actions, the impact of public health epidemics on the global economy and other factors detailed in reports filed by the Company with the United States Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contact:
NewHydrogen, Inc.
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
14 minutes ago
- Business Insider
US Tiger Securities Sticks to Its Buy Rating for XPeng, Inc. ADR (XPEV)
In a report released today, Bo Pei CFA from US Tiger Securities reiterated a Buy rating on XPeng, Inc. ADR, with a price target of $28.00. The company's shares closed today at $20.74. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Pei CFA is ranked #9697 out of 9921 analysts. In addition to US Tiger Securities, XPeng, Inc. ADR also received a Buy from Bank of America Securities's Ming-Hsun Lee in a report issued today. However, on August 11, Bernstein maintained a Hold rating on XPeng, Inc. ADR (NYSE: XPEV). The company has a one-year high of $27.16 and a one-year low of $6.65. Currently, XPeng, Inc. ADR has an average volume of 6.99M.
Yahoo
an hour ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Workday (WDAY) Acquires Flowise to Boost AI Agent Building
Workday, Inc. (NASDAQ:WDAY) is one of the. On August 14, the company announced that it has acquired Flowise, a low-code platform that makes it easy to build AI agents—be it simple chatbots or complex automated workflows. Through the acquisition, Workday is now equipped with an industry-leading agent builder that will boost innovation and enable customers and partners to safely design, launch, and manage AI agents. Tatiana Shepeleva/ Flowise makes the AI development journey easy through its intuitive visual builder and seamless integration across the AI ecosystem, allowing AI agents to be developed smoothly from idea to production. Key benefits that the customers will stand to benefit from include accelerated AI innovation, customization, controllability, and transparency, and responsible AI development. 'Making AI agent development reliable and accessible is a major technical challenge. By bringing Flowise into Workday and investing in its open-source foundation, we are empowering our customers and partners to build and deploy their own AI agents on Workday. Flowise's powerful platform makes this process simple, intuitive, and transparent.' -Peter Bailis, Chief Technology Officer, Workday. Workday, Inc. (NASDAQ:WDAY) provides enterprise cloud applications. While we acknowledge the potential of WDAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data